JP2000514110A - 酸化オリゴ糖 - Google Patents
酸化オリゴ糖Info
- Publication number
- JP2000514110A JP2000514110A JP10503913A JP50391398A JP2000514110A JP 2000514110 A JP2000514110 A JP 2000514110A JP 10503913 A JP10503913 A JP 10503913A JP 50391398 A JP50391398 A JP 50391398A JP 2000514110 A JP2000514110 A JP 2000514110A
- Authority
- JP
- Japan
- Prior art keywords
- oxidized
- oligosaccharide
- solution
- composition according
- oligosaccharides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 92
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 92
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 6
- 230000007062 hydrolysis Effects 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 23
- 150000004676 glycans Chemical class 0.000 claims description 21
- 229920001282 polysaccharide Polymers 0.000 claims description 21
- 239000005017 polysaccharide Substances 0.000 claims description 21
- 229920002201 Oxidized cellulose Polymers 0.000 claims description 16
- 239000012670 alkaline solution Substances 0.000 claims description 16
- 229940107304 oxidized cellulose Drugs 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 14
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 14
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 14
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 3
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 229920002752 Konjac Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 239000000252 konjac Substances 0.000 claims description 3
- 235000010485 konjac Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 229960000292 pectin Drugs 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000004627 regenerated cellulose Substances 0.000 abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000000463 material Substances 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 14
- 108010035532 Collagen Proteins 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 229920001436 collagen Polymers 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 239000004744 fabric Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 11
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 6
- 239000000908 ammonium hydroxide Substances 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 4
- 235000010410 calcium alginate Nutrition 0.000 description 4
- 239000000648 calcium alginate Substances 0.000 description 4
- 229960002681 calcium alginate Drugs 0.000 description 4
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 235000010413 sodium alginate Nutrition 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000001272 nitrous oxide Substances 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 2
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229940045110 chitosan Drugs 0.000 description 2
- 239000000515 collagen sponge Substances 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- IXSZQYVWNJNRAL-UHFFFAOYSA-N etoxazole Chemical compound CCOC1=CC(C(C)(C)C)=CC=C1C1N=C(C=2C(=CC=CC=2F)F)OC1 IXSZQYVWNJNRAL-UHFFFAOYSA-N 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C08B15/02—Oxycellulose; Hydrocellulose; Cellulosehydrate, e.g. microcrystalline cellulose
- C08B15/04—Carboxycellulose, e.g. prepared by oxidation with nitrogen dioxide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G3/00—Glycosides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/20—Post-etherification treatments of chemical or physical type, e.g. mixed etherification in two steps, including purification
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.平均分子量が1000ダルトン乃至50000ダルトンの範囲にある酸化 オリゴ糖組成物。 2.酸化された細菌性もしくは植物性多糖から誘導された請求項1に記載のオ リゴ糖組成物。 3.酸化された動物性多糖または酸化された合成多糖から誘導された請求項1 に記載のオリゴ糖組成物。 4.酸化セルロースまたは酸化セルロース誘導体から誘導された請求項1に記 載のオリゴ糖組成物。 5.デキストラン、ゲランゴム、キサンタンゴム、寒天、デンプン、こんにゃ く、カラゲナン、グアールゴム、ペクチン、カルボキシメチルセルロース、メチ ルヒドロキシプロピルセルロース、酢酸セルロース、メチルセルロース、リン酸 セルロース、エチルセルロースまたはイヌリンの酸化誘導体から誘導された請求 項1に記載のオリゴ糖組成物。 6.平均分子量が5000ダルトン乃至25000ダルトンの範囲にある請求 項1乃至請求項5のいずれか1項に記載のオリゴ糖組成物。 7.請求項1乃至請求項6のいずれか1項に記載の酸化オリゴ糖組成物を含む 、局所、経口もしくは非経口投与用医薬組成物。 8.酸化オリゴ糖は薬理活性なペプチドもしくはタンパク質に結合されている 請求項7に記載の医薬組成物。 9.ペプチドもしくはタンパク質は成長因子である請求項8に記載の医薬組成 物。 10.創傷ドレッシングとして、あるいは創傷ドレッシングにおいて用いる組 成物を製造するための請求項1乃至請求項6のいずれか1項に記載の酸化オリゴ 糖組成物の使用。 11.薬理活性薬剤が前記創傷ドレッシング全体にわたってほぼ均一に分配さ れている請求項8に記載の使用。 12.前記薬理活性薬剤は抗生物質、防腐剤またはタンパク質成長因子である 請求項11に記載の使用。 13.(a)平均分子量が少なくとも5000の酸化多糖を、前記多糖の部分 加水分解を生じさせるのに充分な時間、或る温度で、アルカリ性水溶液で処理す る工程、および (b)その結果生じる酸化オリゴ糖を前記溶液から回収する工程を含む、 酸化オリゴ糖の製造方法。 14.アルカリ性溶液はアルカリ金属の水酸化物または炭酸塩である請求項1 3に記載の方法。 15.酸化オリゴ糖は、酸を用いてpHを7以下に調整することにより前記溶 液から回収される請求項13または請求項14に記載の方法。 16.酸は濃鉱酸である請求項15に記載の方法。 17.請求項13乃至請求項16のいずれか1項に記載の組成物の製造方法で あって、 (a)酸化オリゴ糖のアルカリ性溶液を供給する工程、 (b)前記アルカリ性溶液に治療活性薬剤を溶解または分散させる工程、 および (c)前記溶液または分散液のpHを下げて前記酸化オリゴ糖を沈殿させ る工程を含む方法。 18.請求項13乃至請求項16のいずれか1項に記載の組成物の製造方法で あって、 (a)酸化オリゴ糖のアルカリ性溶液を供給する工程、 (b)前記アルカリ性溶液に治療活性薬剤を溶解または分散させる工程、 および (c)前記溶液または分散液から溶媒を除去する工程を含む方法。 19.溶媒は工程(c)において凍結乾燥により除去される請求項18に記載 の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9613683A GB2314840B (en) | 1996-06-28 | 1996-06-28 | Oxidized oligosaccharides and pharmaceutical compositions |
GB9613683.3 | 1996-06-28 | ||
PCT/GB1997/001726 WO1998000446A1 (en) | 1996-06-28 | 1997-06-27 | Oxidized oligosaccharides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008314228A Division JP5208707B2 (ja) | 1996-06-28 | 2008-12-10 | 酸化セルロースの製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000514110A true JP2000514110A (ja) | 2000-10-24 |
JP4302187B2 JP4302187B2 (ja) | 2009-07-22 |
Family
ID=10796095
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50391398A Expired - Lifetime JP4302187B2 (ja) | 1996-06-28 | 1997-06-27 | 酸化オリゴ糖 |
JP2008314228A Expired - Lifetime JP5208707B2 (ja) | 1996-06-28 | 2008-12-10 | 酸化セルロースの製造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008314228A Expired - Lifetime JP5208707B2 (ja) | 1996-06-28 | 2008-12-10 | 酸化セルロースの製造方法 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0907664B1 (ja) |
JP (2) | JP4302187B2 (ja) |
KR (1) | KR20000022286A (ja) |
AT (1) | ATE195742T1 (ja) |
AU (1) | AU725296B2 (ja) |
BR (1) | BR9710003A (ja) |
CA (1) | CA2258849C (ja) |
CZ (1) | CZ294839B6 (ja) |
DE (1) | DE69702911T2 (ja) |
ES (1) | ES2148991T3 (ja) |
GB (1) | GB2314840B (ja) |
GR (1) | GR3034853T3 (ja) |
HU (1) | HUP9903404A3 (ja) |
PL (1) | PL189194B1 (ja) |
PT (1) | PT907664E (ja) |
WO (1) | WO1998000446A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005537882A (ja) * | 2002-09-11 | 2005-12-15 | ジョンソン・アンド・ジョンソン・メディカル・リミテッド | 陰イオン多糖と銀の複合体を含む創傷包帯材料 |
JP2007099785A (ja) * | 2005-09-30 | 2007-04-19 | Toho Chem Ind Co Ltd | カチオン変性ペクチン及び該物質を含む化粧料組成物 |
JP2009507102A (ja) * | 2005-09-02 | 2009-02-19 | オールトレイセル・ディベロップメント・サービシズ・リミテッド | ポリアンヒドログルクロン酸及びその塩を調製する方法 |
JP2011213985A (ja) * | 2010-03-17 | 2011-10-27 | Shizuokaken Koritsu Daigaku Hojin | トリアセチルセルロースブロック共重合体、その中間体、充填剤、および、界面活性剤 |
JP2018515592A (ja) * | 2015-05-22 | 2018-06-14 | シャンハイ グリーン バレー ファーマシューティカル カンパニー リミテッド | 酸化型β−1,4−グルクロン酸オリゴマーおよびその製造方法と使用 |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2344519B (en) * | 1998-12-07 | 2004-05-19 | Johnson & Johnson Medical Ltd | Sterile therapeutic compositions |
GB9900150D0 (en) | 1999-01-05 | 1999-02-24 | Unilever Plc | Treatment for fabrics |
GB2354708B (en) * | 1999-10-01 | 2004-06-02 | Johnson & Johnson Medical Ltd | Compositions for the treatment of wound contracture |
US6309454B1 (en) | 2000-05-12 | 2001-10-30 | Johnson & Johnson Medical Limited | Freeze-dried composite materials and processes for the production thereof |
AU784607B2 (en) * | 2000-05-12 | 2006-05-11 | Systagenix Wound Management Ip Co. B.V. | Free radical scavenging compositions |
AU782756B2 (en) * | 2000-05-12 | 2005-08-25 | Systagenix Wound Management Ip Co. B.V. | Solid composition exhibiting selective binding to dissolved iron |
WO2002087643A1 (fr) * | 2001-04-30 | 2002-11-07 | Beijing Textile Research Institute | Matieres styptiques de derives ether de cellulose hydrosolubles |
US20030118651A1 (en) * | 2001-12-21 | 2003-06-26 | Jampani Hanuman B. | Bio-compatible means for controlled drug delivery to tissue and method of use |
US20030124087A1 (en) * | 2001-12-26 | 2003-07-03 | Amitie Co. Ltd. | Anti-adhesion barrier |
US20040101547A1 (en) * | 2002-11-26 | 2004-05-27 | Pendharkar Sanyog Manohar | Wound dressing containing aldehyde-modified regenerated polysaccharide |
US7279177B2 (en) | 2002-06-28 | 2007-10-09 | Ethicon, Inc. | Hemostatic wound dressings and methods of making same |
US7252837B2 (en) | 2002-06-28 | 2007-08-07 | Ethicon, Inc. | Hemostatic wound dressing and method of making same |
CA2495541C (en) * | 2002-09-11 | 2011-07-12 | Johnson & Johnson Medical Limited | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
GB2393120A (en) * | 2002-09-18 | 2004-03-24 | Johnson & Johnson Medical Ltd | Compositions for wound treatment |
US8685943B2 (en) | 2003-03-12 | 2014-04-01 | Hill's Pet Nutrition, Inc. | Methods for reducing diarrhea in a companion animal |
US7019191B2 (en) | 2003-03-25 | 2006-03-28 | Ethicon, Inc. | Hemostatic wound dressings and methods of making same |
DE10319808A1 (de) * | 2003-04-28 | 2004-11-18 | Friedrich-Schiller-Universität Jena | Verwendung von Polysaccharid-Derivaten als Mittel zur Stimulierung der Zellproliferation |
GB2408206B (en) | 2003-11-18 | 2007-11-28 | Johnson & Johnson Medical Ltd | Antioxidant and antimicrobial wound dressing materials |
US20040265371A1 (en) | 2003-06-25 | 2004-12-30 | Looney Dwayne Lee | Hemostatic devices and methods of making same |
EP1689787A2 (en) | 2003-11-28 | 2006-08-16 | Eastman Chemical Company | Cellulose interpolymers and method of oxidation |
AU2005286771B2 (en) * | 2004-09-17 | 2011-04-21 | David M. Dixon | Wound care dressing and method using same |
US9358318B2 (en) | 2004-10-20 | 2016-06-07 | Ethicon, Inc. | Method of making a reinforced absorbable multilayered hemostatic wound dressing |
US20060093655A1 (en) | 2004-10-20 | 2006-05-04 | Lillian Bar | Method for making a reinforced absorbable multilayered hemostatic wound dressing |
BRPI0516220B8 (pt) | 2004-10-20 | 2021-06-22 | Ethicon Inc | tecido de multicamadas absorvíveis reforçadas para aplicação em dispositivos médicos e método de fabricação |
GB2444232A (en) | 2006-11-30 | 2008-06-04 | Ethicon Inc | Wound dressing compositions comprising cell lysates |
US20090074837A1 (en) * | 2007-09-19 | 2009-03-19 | Ut-Battelle, Llc | Bioresorbable Calcium-Deficient Hydroxyapatite Hydrogel Composite |
US9376648B2 (en) | 2008-04-07 | 2016-06-28 | The Procter & Gamble Company | Foam manipulation compositions containing fine particles |
JP2010284216A (ja) * | 2009-06-09 | 2010-12-24 | Hogi Medical:Kk | カルボキシメチルセルロース構造体及びその製造方法 |
US9139662B2 (en) * | 2011-03-30 | 2015-09-22 | Nippon Paper Industries Co., Ltd. | Method for producing cellulose nanofibers |
DE102011007528A1 (de) * | 2011-04-15 | 2012-10-18 | Aesculap Aktiengesellschaft | Thixotrope Zusammensetzung, insbesondere zur postchirurgischen Adhäsionsprophylaxe |
EP2720667A2 (en) * | 2011-06-16 | 2014-04-23 | Unilever PLC | Aqueous gels |
WO2017206131A1 (en) * | 2016-06-02 | 2017-12-07 | Gunze Limited | Medical fiber structure and medical laminate |
KR102294257B1 (ko) * | 2019-04-30 | 2021-08-26 | 한양대학교 에리카산학협력단 | 바이오셀룰로오스-펩티드 복합체 및 이의 제조방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE360128C (de) * | 1921-01-03 | 1922-09-29 | Albert Reychler Dr | Verfahren zur Herstellung von Staerkeloesungen |
US2517772A (en) * | 1945-05-11 | 1950-08-08 | Parke Davis & Co | Neutralized oxidized cellulose products |
US3598622A (en) * | 1969-02-19 | 1971-08-10 | Cpc International Inc | Alkali treated starch compositions |
AR243204A1 (es) * | 1986-11-21 | 1993-07-30 | Ajorca Sa | Un metodo para la depolimerizacion quimica de polisacaridos. |
CA2033046C (en) * | 1990-01-12 | 1999-08-03 | Lowell Saferstein | Process for preparing a neutralized oxidized cellulose product and its method of use |
CN1035803C (zh) * | 1990-07-24 | 1997-09-10 | 中国化工进出口总公司 | 可溶性止血织物 |
CA2071137A1 (en) * | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
JP3357996B2 (ja) * | 1993-03-26 | 2002-12-16 | ライオン株式会社 | 金属イオン封鎖性オリゴマー化合物の製造方法及びそのオリゴマー化合物を含む洗浄剤組成物 |
US5414079A (en) * | 1993-08-03 | 1995-05-09 | Biocontrol Incorporated | Oxidized cellulose |
DE4411681A1 (de) * | 1994-04-05 | 1995-10-12 | Hoechst Ag | Verfahren zur Herstellung niedermolekularer Polysaccharidether |
-
1996
- 1996-06-28 GB GB9613683A patent/GB2314840B/en not_active Revoked
-
1997
- 1997-06-27 DE DE69702911T patent/DE69702911T2/de not_active Expired - Lifetime
- 1997-06-27 HU HU9903404A patent/HUP9903404A3/hu unknown
- 1997-06-27 AT AT97928373T patent/ATE195742T1/de not_active IP Right Cessation
- 1997-06-27 JP JP50391398A patent/JP4302187B2/ja not_active Expired - Lifetime
- 1997-06-27 EP EP97928373A patent/EP0907664B1/en not_active Expired - Lifetime
- 1997-06-27 ES ES97928373T patent/ES2148991T3/es not_active Expired - Lifetime
- 1997-06-27 WO PCT/GB1997/001726 patent/WO1998000446A1/en active IP Right Grant
- 1997-06-27 BR BR9710003-0A patent/BR9710003A/pt not_active IP Right Cessation
- 1997-06-27 AU AU32693/97A patent/AU725296B2/en not_active Expired
- 1997-06-27 PT PT97928373T patent/PT907664E/pt unknown
- 1997-06-27 CZ CZ19984274A patent/CZ294839B6/cs not_active IP Right Cessation
- 1997-06-27 PL PL97330825A patent/PL189194B1/pl unknown
- 1997-06-27 KR KR1019980710708A patent/KR20000022286A/ko not_active Application Discontinuation
- 1997-06-27 CA CA002258849A patent/CA2258849C/en not_active Expired - Lifetime
-
2000
- 2000-11-15 GR GR20000402542T patent/GR3034853T3/el unknown
-
2008
- 2008-12-10 JP JP2008314228A patent/JP5208707B2/ja not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005537882A (ja) * | 2002-09-11 | 2005-12-15 | ジョンソン・アンド・ジョンソン・メディカル・リミテッド | 陰イオン多糖と銀の複合体を含む創傷包帯材料 |
JP4808402B2 (ja) * | 2002-09-11 | 2011-11-02 | ジョンソン・アンド・ジョンソン・メディカル・リミテッド | 陰イオン多糖と銀の複合体を含む創傷包帯材料 |
JP2009507102A (ja) * | 2005-09-02 | 2009-02-19 | オールトレイセル・ディベロップメント・サービシズ・リミテッド | ポリアンヒドログルクロン酸及びその塩を調製する方法 |
JP2007099785A (ja) * | 2005-09-30 | 2007-04-19 | Toho Chem Ind Co Ltd | カチオン変性ペクチン及び該物質を含む化粧料組成物 |
JP2011213985A (ja) * | 2010-03-17 | 2011-10-27 | Shizuokaken Koritsu Daigaku Hojin | トリアセチルセルロースブロック共重合体、その中間体、充填剤、および、界面活性剤 |
JP2018515592A (ja) * | 2015-05-22 | 2018-06-14 | シャンハイ グリーン バレー ファーマシューティカル カンパニー リミテッド | 酸化型β−1,4−グルクロン酸オリゴマーおよびその製造方法と使用 |
JP2019131574A (ja) * | 2015-05-22 | 2019-08-08 | シャンハイ グリーン バレー ファーマシューティカル カンパニー リミテッド | 酸化型β−1,4−グルクロン酸オリゴマーおよびその製造方法と使用 |
US10898508B2 (en) | 2015-05-22 | 2021-01-26 | Shanghai Green Valley Pharmaceutical Co., Ltd. | Oxidized β-1,4-oligoglucuronic acid, and preparation method therefor and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
PL189194B1 (pl) | 2005-07-29 |
HUP9903404A2 (hu) | 2000-03-28 |
JP5208707B2 (ja) | 2013-06-12 |
KR20000022286A (ko) | 2000-04-25 |
JP4302187B2 (ja) | 2009-07-22 |
HUP9903404A3 (en) | 2001-03-28 |
CA2258849C (en) | 2008-01-22 |
CA2258849A1 (en) | 1998-01-08 |
CZ427498A3 (cs) | 1999-05-12 |
GB2314840A (en) | 1998-01-14 |
ES2148991T3 (es) | 2000-10-16 |
AU3269397A (en) | 1998-01-21 |
CZ294839B6 (cs) | 2005-03-16 |
AU725296B2 (en) | 2000-10-12 |
GB9613683D0 (en) | 1996-08-28 |
PT907664E (pt) | 2000-12-29 |
EP0907664B1 (en) | 2000-08-23 |
BR9710003A (pt) | 2000-01-11 |
PL330825A1 (en) | 1999-06-07 |
GR3034853T3 (en) | 2001-02-28 |
DE69702911T2 (de) | 2001-02-22 |
WO1998000446A1 (en) | 1998-01-08 |
DE69702911D1 (de) | 2000-09-28 |
ATE195742T1 (de) | 2000-09-15 |
EP0907664A1 (en) | 1999-04-14 |
GB2314840B (en) | 2000-09-06 |
JP2009102645A (ja) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5208707B2 (ja) | 酸化セルロースの製造方法 | |
JP4230767B2 (ja) | ヒアルロン酸の架橋結合型アミド誘導体及びその製造方法。 | |
US6509039B1 (en) | Crosslinked products of biopolymers containing amino groups | |
AU2009302160B2 (en) | Polysaccharides containing carboxyl functional groups substituted by a hydrophobic alcohol derivative | |
JP3512184B2 (ja) | 乳化後の分散相の化学組成の変化による乳状微粒子の製造法 | |
US20100137456A1 (en) | Polysaccharides functionalized by tryptophan derivatives | |
CA2288983C (en) | Covalently linked n,o-carboxymethylchitosan and uses thereof | |
JP2002529549A (ja) | カルボキシル化多糖の架橋方法 | |
JPS6147413A (ja) | 活性化合物デポー剤 | |
JPH10502665A (ja) | 創傷治癒剤 | |
JP2002528518A (ja) | 粘液付着性ポリマー、その使用およびその製造法 | |
JP2000116765A (ja) | 癒着防止用材料 | |
EP1147148A1 (en) | Dextran-maleic acid monoesters and hydrogels based thereon | |
CN113521305A (zh) | 一种蜂胶醇提物-环糊精-壳聚糖-黏蛋白缓释凝胶及其制备方法和应用 | |
JPS6087219A (ja) | 活性物質デポー | |
JP2004041586A (ja) | 生体適合性材料およびその製造方法 | |
JP4469145B2 (ja) | 多糖架橋体及びその製造法。 | |
JP4460662B2 (ja) | 溶解速度が制御されたヒアルロン酸ゲル及びその製造方法 | |
JP4215308B2 (ja) | 複合キトサン化合物及びその用途 | |
JPH0586234B2 (ja) | ||
JP2006291097A (ja) | ヒアルロン酸誘導体、およびその製造法 | |
JP2000178304A (ja) | ヒアルロン酸ゲルの製造方法 | |
JP2000191703A (ja) | ヒアルロン酸ゲル及びその製造方法 | |
JPH0597661A (ja) | 薬物徐放剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040625 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071218 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080318 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080618 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090203 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090319 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090331 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090422 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120501 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120501 Year of fee payment: 3 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130501 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |